Chinese biotech’s research chief calls decision ‘unfortunate’ as zero-Covid policy strangles economy
Progress stalls on jabs that offer protection against a variety of variants or other coronaviruses
Setback for a method hoped to provide better protection against virus transmission
Pharma company still ‘eager’ to collaborate with Beijing, despite collapse of initial talks
Experts are concerned that the US isn’t doing enough to support the development of the next wave of vaccines and treatments that the world needs to fight the Covid-19 pandemic
Top jab makers lose combined $10bn of market value amid fears over growing public apathy
Chief US medical adviser says anti-vax attitudes could spill over and cause disease outbreaks
Ashish Jha says vaccines and drugs will be limited if Congress fails to approve further funding
Some health experts say vaccination campaign risks undermining public trust
Booster yielded efficacy as high as 80% in one group, Lancet study shows
EMA backs jabs targeting the strain that appeared in 2019 and original version of Omicron
FDA clears jabs despite lack of human trials in effort to curb winter wave of Covid infections
Therapeutic research initiative aims to raise $1bn after receiving largest single donation in Australian medical history
Having helped create the AstraZeneca Covid-19 drug, the Oxford scientist has another urgent goal, to eliminate malaria through vaccination
US biotech claims rival Covid vaccine makers infringed patents underpinning jabs developed to combat the pandemic
Covid exposed Africa’s dependence on overseas production but local initiatives show potential
Federal requirement for non-citizen travellers thwarts tennis star’s return to New York
Experts hit out at monkeypox response: ‘We’re actually at the most vulnerable we’ve ever been’
Vaccine targeting BA.4/BA.5 could become first shot to win green light without human trials
EU health commissioner calls for governments to prepare for outbreaks amid complacency in summer months
Group developing jab with Sanofi that could have benefits
Pharma group alleges breach of non-compete agreement to delay start date of departing business development official
Moderna’s two-strain shot will target both the original strain and BA.1 in step with European regulators
US drugmaker’s shares fall more than 30% as it blames weak demand for jabs
German biotech aims for ‘prolonged and broad protection’ as sales and earnings miss expectations
International Edition